Importantly, a weak IFN response, which results in a dampened P-ISGF3 signaling but robust U-ISGF3 signaling, leading to an IFN-related DNA damage resistance signature (IRDS), can correspond to therapeutic resistance and poor outcomes in a variety of cancers [13–15]. The gene discussed is IRF9; the disease is cancer.